biotech
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
House Speaker Plans Vote on Biosecure Act Amid Broader China Legislation Push
House Speaker, Biosecure Act, China Legislation, National Security, Biotech Companies
Biovance Capital Partners Launches with €51M to Boost Biotech in Southern Europe
Biovance Capital Partners, Biotech, Southern Europe, Venture Capital, Healthcare
Myricx Secures $114M Funding with Lilly’s Support for ADC Development
Myricx, Eli Lilly, ADCs, Biotech Funding, Series A
Artiva Pursues IPO to Fund NK Cell Therapy After Losing Merck Partnership
Artiva, Merck, IPO, NK Cell Therapy, Biotech, Partnership, Funding
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology